Microbix BiosystemsMBXBF 51 Receivables Turnover is 0.94 as of Mar. 2026. GuruFocus rates MBXBF with a GF Score™ of 51/100 and a GF Value™ of $0.17 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 840 Biotechnology companies, Microbix Biosystems ranks better than 51.07% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Microbix Biosystems's Revenue for the
three
months ended in Mar. 2026 was $2.46 Mil. Microbix Biosystems's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2.63 Mil.
Hence, Microbix Biosystems's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.94.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Microbix Biosystems Receivables Turnover Related Terms
Microbix Biosystems Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBXBF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Microbix Biosystems's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (MBXBF) has a Receivables Turnover of 0.94 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #411 out of 840 companies in the Biotechnology industry, placing it in the top 48.9%.
Is Microbix Biosystems' Receivables Turnover too high?
Microbix Biosystems' current Receivables Turnover is 0.94. The Biotechnology industry median Receivables Turnover is 5.30. Microbix Biosystems' value of 0.94 is 82.3% below this industry median. Based on the distribution chart, Microbix Biosystems ranks #411 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #411 out of 840 companies for Receivables Turnover. This puts Microbix Biosystems in the upper half of its industry. The industry median Receivables Turnover is 5.30. Microbix Biosystems' value of 0.94 is 82.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbix Biosystems's current Receivables Turnover of 0.94 is 82.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Microbix Biosystems and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbix Biosystems's current Receivables Turnover is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.22 — trading 26.5% above its estimated fair value. The current Receivables Turnover is 0.94 and 82.3% below the Biotechnology industry median of 5.30. Microbix Biosystems' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Receivables Turnover is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 26.5% above its estimated GF Value™ of $0.17.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
Receivables Turnover: 0.94
GF Value™: $0.17 vs. price of $0.22 (26.5% above fair value)
Industry Position: 82.3% below the Biotechnology median (#411 of 840)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
51GF Score
Get the complete analysis for MBXBF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
